BIOMAT Database Logo BIOMAT Database Logo

Peripheral administration of an angiotensin II AT(1) receptor antagonist decreases the hypothalamic-pituitary-adrenal response to isolation Stress. 2001

I Armando, and A Carranza, and Y Nishimura, and K L Hoe, and M Barontini, and J A Terrón, and A Falcón-Neri, and T Ito, and A V Juorio, and J M Saavedra
Centro de Investigaciones Endocrinologicas, Consejo Nacional de Investigaciones Cientificas y Tecnicas, Buenos Aires, Buenos Aires 1013, Argentina. saavedrj@irp.nimh.nih.gov

Angiotensin II, which stimulates AT(1) receptors, is a brain and peripheral stress hormone. We pretreated rats with the AT(1) receptor antagonist candesartan for 13 d via sc-implanted osmotic minipumps, followed by 24-h isolation in individual metabolic cages. We measured angiotensin II receptor-type binding and mRNAs and tyrosine hydroxylase mRNA by quantitative autoradiography and in situ hybridization, catecholamines by HPLC, and hormones by RIA. Isolation increased AT(1) receptor binding in hypothalamic paraventricular nucleus as well as anterior pituitary ACTH, and decreased posterior pituitary AVP. Isolation stress also increased AT(1) receptor binding and AT(1B) mRNA in zona glomerulosa and AT(2) binding in adrenal medulla, adrenal catecholamines, tyrosine hydroxylase mRNA, aldosterone, and corticosterone. Candesartan blocked AT(1) binding in paraventricular nucleus and adrenal gland; prevented the isolation-induced alterations in pituitary ACTH and AVP and in adrenal corticosterone, aldosterone, and catecholamines; abolished the increase in AT(2) binding in adrenal medulla; and substantially decreased urinary AVP, corticosterone, aldosterone, and catecholamines during isolation. Peripheral pretreatment with an AT(1) receptor antagonist blocks brain and peripheral AT(1) receptors and inhibits the hypothalamic-pituitary-adrenal response to stress, suggesting a physiological role for peripheral and brain AT(1) receptors during stress and a possible beneficial effect of AT(1) antagonism in stress-related disorders.

UI MeSH Term Description Entries
D007030 Hypothalamo-Hypophyseal System A collection of NEURONS, tracts of NERVE FIBERS, endocrine tissue, and blood vessels in the HYPOTHALAMUS and the PITUITARY GLAND. This hypothalamo-hypophyseal portal circulation provides the mechanism for hypothalamic neuroendocrine (HYPOTHALAMIC HORMONES) regulation of pituitary function and the release of various PITUITARY HORMONES into the systemic circulation to maintain HOMEOSTASIS. Hypothalamic Hypophyseal System,Hypothalamo-Pituitary-Adrenal Axis,Hypophyseal Portal System,Hypothalamic-Pituitary Unit,Hypothalamic Hypophyseal Systems,Hypothalamic Pituitary Unit,Hypothalamo Hypophyseal System,Hypothalamo Pituitary Adrenal Axis,Portal System, Hypophyseal
D007260 Infusion Pumps Fluid propulsion systems driven mechanically, electrically, or osmotically that are used to inject (or infuse) over time agents into a patient or experimental animal; used routinely in hospitals to maintain a patent intravenous line, to administer antineoplastic agents and other drugs in thromboembolism, heart disease, diabetes mellitus (INSULIN INFUSION SYSTEMS is also available), and other disorders. Drug Infusion Systems,Infusion Pump,Infusion Pumps, External,Infusors,Intravenous Drug Delivery System,Intravenous Drug Delivery Systems,Perfusion Pumps,Pumps, Infusion,Drug Infusion System,External Infusion Pump,External Infusion Pumps,Infusion Pump, External,Infusion System, Drug,Infusion Systems, Drug,Infusor,Perfusion Pump,Pump, External Infusion,Pump, Infusion,Pump, Perfusion,Pumps, External Infusion,Pumps, Perfusion,System, Drug Infusion,Systems, Drug Infusion
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008297 Male Males
D010907 Pituitary Hormones Hormones secreted by the PITUITARY GLAND including those from the anterior lobe (adenohypophysis), the posterior lobe (neurohypophysis), and the ill-defined intermediate lobe. Structurally, they include small peptides, proteins, and glycoproteins. They are under the regulation of neural signals (NEUROTRANSMITTERS) or neuroendocrine signals (HYPOTHALAMIC HORMONES) from the hypothalamus as well as feedback from their targets such as ADRENAL CORTEX HORMONES; ANDROGENS; ESTROGENS. Hormones, Pituitary
D010913 Pituitary-Adrenal System The interactions between the anterior pituitary and adrenal glands, in which corticotropin (ACTH) stimulates the adrenal cortex and adrenal cortical hormones suppress the production of corticotropin by the anterior pituitary. Pituitary Adrenal System,Pituitary-Adrenal Systems,System, Pituitary-Adrenal,Systems, Pituitary-Adrenal
D011945 Receptors, Angiotensin Cell surface proteins that bind ANGIOTENSINS and trigger intracellular changes influencing the behavior of cells. Angiotensin Receptor,Angiotensin Receptors,Angiotensin II Receptor,Angiotensin III Receptor,Receptor, Angiotensin II,Receptor, Angiotensin III,Receptor, Angiotensin
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002395 Catecholamines A general class of ortho-dihydroxyphenylalkylamines derived from TYROSINE. Catecholamine,Sympathin,Sympathins
D006728 Hormones Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects. Hormone,Hormone Receptor Agonists,Agonists, Hormone Receptor,Receptor Agonists, Hormone

Related Publications

I Armando, and A Carranza, and Y Nishimura, and K L Hoe, and M Barontini, and J A Terrón, and A Falcón-Neri, and T Ito, and A V Juorio, and J M Saavedra
Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors.
July 2000, Brain research,
I Armando, and A Carranza, and Y Nishimura, and K L Hoe, and M Barontini, and J A Terrón, and A Falcón-Neri, and T Ito, and A V Juorio, and J M Saavedra
Angiotensin(1-7) is an antagonist at the type 1 angiotensin II receptor.
December 1994, Journal of hypertension,
I Armando, and A Carranza, and Y Nishimura, and K L Hoe, and M Barontini, and J A Terrón, and A Falcón-Neri, and T Ito, and A V Juorio, and J M Saavedra
Angiotensin II AT1 receptor blockade prevents the hypothalamic corticotropin-releasing factor response to isolation stress.
April 2007, Brain research,
I Armando, and A Carranza, and Y Nishimura, and K L Hoe, and M Barontini, and J A Terrón, and A Falcón-Neri, and T Ito, and A V Juorio, and J M Saavedra
Central administration of the neurotensin receptor antagonist, SR48692, modulates diurnal and stress-related hypothalamic-pituitary-adrenal activity.
August 1997, Neuroendocrinology,
I Armando, and A Carranza, and Y Nishimura, and K L Hoe, and M Barontini, and J A Terrón, and A Falcón-Neri, and T Ito, and A V Juorio, and J M Saavedra
Interleukin-1 Receptor Antagonist Decreases Hypothalamic Oxidative Stress During Experimental Sepsis.
August 2016, Molecular neurobiology,
I Armando, and A Carranza, and Y Nishimura, and K L Hoe, and M Barontini, and J A Terrón, and A Falcón-Neri, and T Ito, and A V Juorio, and J M Saavedra
Chronic administration of the non-peptide CRH type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress.
January 1999, Life sciences,
I Armando, and A Carranza, and Y Nishimura, and K L Hoe, and M Barontini, and J A Terrón, and A Falcón-Neri, and T Ito, and A V Juorio, and J M Saavedra
Increased angiotensin II AT(1) receptor expression in paraventricular nucleus and hypothalamic-pituitary-adrenal axis stimulation in AT(2) receptor gene disrupted mice.
September 2002, Neuroendocrinology,
I Armando, and A Carranza, and Y Nishimura, and K L Hoe, and M Barontini, and J A Terrón, and A Falcón-Neri, and T Ito, and A V Juorio, and J M Saavedra
Chronic administration of an angiotensin II receptor antagonist resets the hypothalamic-pituitary-adrenal (HPA) axis and improves the affect of patients with diabetes mellitus type 2: preliminary results.
January 2008, Stress (Amsterdam, Netherlands),
I Armando, and A Carranza, and Y Nishimura, and K L Hoe, and M Barontini, and J A Terrón, and A Falcón-Neri, and T Ito, and A V Juorio, and J M Saavedra
Sleep restriction alters the hypothalamic-pituitary-adrenal response to stress.
May 2002, Journal of neuroendocrinology,
I Armando, and A Carranza, and Y Nishimura, and K L Hoe, and M Barontini, and J A Terrón, and A Falcón-Neri, and T Ito, and A V Juorio, and J M Saavedra
Pituitary-adrenal response to stress in rats with hypothalamic islands.
December 1969, Brain research,
Copied contents to your clipboard!